Protagenic Therapeutics 8-K Report: Key Stock Insights for February 2025

Based on the provided section of the financial report, here are the key insights and information extracted:

1. Company Information:

• Entity Name: Protagenic Therapeutics, Inc.
• CIK: 0001022899
• Address: 149 Fifth Avenue, Suite 500, New York, NY 10010
• Phone: 212-994-8200

2. Filing Details:

• Type of Filing: 8-K
• Filing Date: February 21, 2025
• SEC Central Index Key (CIK): 0001022899
• SEC File Number: 001-12555

3. Stock Information:

• Common Stock Ticker: PTIX (traded on NASDAQ)
• Common Stock Warrants Ticker: PTIXW (traded on NASDAQ)

4. Reporting Context:

• Report Date: The report covers a specific date, February 21, 2025.
• Type of Stock: The report mentions "Common Stock" and "Common Stock Warrants," indicating different classes of financial instruments.

5. Units of Measure:

• The financial data is provided in USD (U.S. Dollars) and shares, indicating the company is reporting in terms of its equity structure and stock-related instruments.

6. Dimensions of Reporting:

• The report specifies explicit members for stock classes, indicating a structured approach to classifying and presenting stockholder equity and related securities.

7. No Financial Figures Provided:

• The provided section does not include specific financial figures or metrics, such as earnings, revenue, or share counts.

Summary:

The document is an 8-K filing by Protagenic Therapeutics, Inc. on February 21, 2025, detailing aspects of its common stock and warrants. While it does not provide numerical financial data, it confirms the company's trading symbols on NASDAQ and outlines the basic entity information and reporting context. Further financial details would likely be found in the complete report or subsequent filings.